Who Paid My Doc
Jhon Guerra
Pediatric Hematology-Oncology San Juan, PR Medical Doctor
NPI 1861547192 CMS profile 1071131
Upr Recinto De Ciencias Medicas Hospital Pediatrico, Edificio A Oficina Bc 12, San Juan, PR 00936
General payments
$2,117
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$9,053
Through program year 2025, Jhon Guerra of San Juan, PR is reported in the CMS Open Payments database as having received $2,117 across 54 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $9,053 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 62nd percentile of Pediatric Hematology-Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $740 | 16 | |
| 2024 | General | $196 | 5 | |
| 2023 | General | $429 | 11 | |
| 2022 | General | $195 | 6 | |
| 2021 | General | $100 | 1 | |
| 2020 | General | $25 | 2 | |
| 2019 | General | $431 | 13 |
Beside peers
- Jhon Guerra
- Pediatric Hematology-Oncology median
- Middle half of Pediatric Hematology-Oncology
- National median
In program year 2025, general payments to Jhon Guerra were reported at $740. Among 1,352 Pediatric Hematology-Oncology profiles paid that year, the median was $204 and the middle half received between $80 and $2,819.
Show as a table
| Year | Jhon Guerra | Pediatric Hematology-Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $431 | $184 | $69–$2,094 | $163 |
| 2020 | $25 | $220 | $37–$3,941 | $114 |
| 2021 | $100 | $366 | $63–$4,909 | $132 |
| 2022 | $195 | $181 | $66–$2,775 | $149 |
| 2023 | $429 | $175 | $62–$2,600 | $160 |
| 2024 | $196 | $227 | $66–$2,992 | $164 |
| 2025 | $740 | $204 | $80–$2,819 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
54 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Hematology-Oncology in Puerto Rico
Rocio Rivera-Valentin
Pediatric Hematology-Oncology · San Juan, PR
Moises Garcia Rosa
Pediatric Hematology-Oncology · Rio Piedras, PR
Maria Echevarria-Escudero
Pediatric Hematology-Oncology · Santurce, PR
Enid Rivera - Jimenez
Pediatric Hematology-Oncology · Rio Piedras, PR
Lourdes Fernandez Nunez
Pediatric Hematology-Oncology · Caguas, PR
Rosa Diaz
Pediatric Hematology-Oncology · Bayamon, PR
Related records
Pediatric Hematology-Oncology in Puerto Rico
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Hematology-Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Puerto Rico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.